This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Quintiles Infosario Receives Computerworld Data+ Editor’s Choice Award

Quintiles has been recognized for its pioneering work creating big data solutions that help pharmaceutical organizations improve their probability of success throughout the drug development process, with a Computerworld Data+ Editor’s Choice Award for its Quintiles Infosario ® platform.

"The drug development process is predicated upon the availability of high quality data with which to collaborate and make informed decisions at every step of the way during the evolution of a product or treatment," said Quintiles Chief Information Officer Richard Thomas. "We are delighted to receive this award which highlights the work of our outstanding team of dedicated professionals, partners and customers who all contributed in the development of technologies that power our Quintiles Infosario platform."

Quintiles Infosario is an end-to-end suite of technologies that power the pharmaceutical product development process. Making innovative use of advances in big data technologies, Infosario is able to break down silos combining massive quantities of scientific and operational data collected during clinical development with tens of millions of real-world patient medical records and population data. Empowering researchers and drug developers with the knowledge locked in this data improves decision making, and ultimately increases the probability of success at every step in a product’s lifecycle.

Computerworld’s Data+ awards recognize the very best projects that illustrate how big data can be mined and analyzed to predict trends and improve the probability of success. Honorees are being recognized in the August 26th issue of Computerworld, on Computerworld.com and at Computerworld’s 2013 Data+ conference.

“The organizations honored in this year’s Data+ Editor’s Choice awards program have unearthed the business value that’s rooted throughout big data,” said Scot Finnie, editor in chief, Computerworld. “The projects spotlighted are tapping into big data to analyze and influence customer behavior, drive new business revenues and predict future trends. Each of the organizations is raising our understanding of big data to new levels, while at the same time opening the door for other organizations to follow their lead. It’s an exciting time in the big data field.”

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com

Click here to subscribe to Mobile Alerts for Quintiles.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,081.65 -121.72 -0.67%
S&P 500 2,096.30 -11.48 -0.54%
NASDAQ 4,966.51 -13.3910 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs